Swiss National Bank Has $96.94 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Swiss National Bank increased its Kenvue stake by 6.9% in the first quarter, bringing its holdings to 5.62 million shares valued at about $96.94 million.
• Kenvue reported better-than-expected quarterly results, with EPS of $0.32 versus the $0.27 estimate and revenue of $3.91 billion, up 4.5% year over year.
• The company also paid a quarterly dividend of $0.2075 per share, implying an annualized yield of about 4.4%, while analysts currently rate the stock a Hold with an average price target of $19.50.

Swiss National Bank lifted its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 6.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,622,946 shares of the company's stock after purchasing an additional 364,000 shares during the quarter. Swiss National Bank owned 0.29% of Kenvue worth $96,940,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in Kenvue in the 4th quarter worth $756,862,000. Independent Franchise Partners LLP increased its holdings in Kenvue by 56.3% during the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company's stock worth $830,527,000 after purchasing an additional 17,343,785 shares in the last quarter. Sculptor Capital LP raised its stake in shares of Kenvue by 1,023.5% in the 4th quarter. Sculptor Capital LP now owns 12,886,328 shares of the company's stock valued at $222,289,000 after purchasing an additional 11,739,328 shares during the period. Capitolis Liquid Global Markets LLC raised its stake in shares of Kenvue by 1,116.8% in the 4th quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company's stock valued at $188,905,000 after purchasing an additional 10,050,999 shares during the period. Finally, Cibc World Markets Corp bought a new stake in shares of Kenvue in the fourth quarter valued at about $162,193,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity

In related news, General Counsel Matthew Orlando sold 38,491 shares of the business's stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.59% of the company's stock.

Kenvue Trading Up 0.1%

Shares of Kenvue stock opened at $19.00 on Tuesday. The firm has a 50-day moving average of $18.23 and a 200-day moving average of $17.87. The stock has a market cap of $36.47 billion, a PE ratio of 22.35, a PEG ratio of 1.44 and a beta of 0.47. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 earnings per share. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue's payout ratio is presently 97.65%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Citigroup reduced their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Wednesday, April 15th. UBS Group lifted their price objective on shares of Kenvue from $18.00 to $20.00 and gave the company a "neutral" rating in a report on Thursday. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Barclays reduced their target price on shares of Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a report on Tuesday, April 14th. Finally, Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $19.50.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.